Texas has the largest population of any state without a state income tax, an active and visible Board of Pharmacy, and a regulatory framework that has been more attentive to compounded GLP-1s than most. The Texas State Board of Pharmacy has prosecuted salt-form tirzepatide cases, scrutinized sterile compounding practices, and issued guidance that affects how out-of-state telehealth companies serve Texas residents. The result is a state where patient access is fully available but the operational details matter more than in many other markets.
This guide covers the Texas-specific framework, the post-shortage compounding landscape, what coverage exists, and what Texas patients should look for when comparing options.
Texas pharmacy permit structure
Texas uses a class-based permit system administered by the Texas State Board of Pharmacy (TSBP). The classes most relevant to GLP-1 prescribing:
- Class A (community pharmacy): Retail pharmacies dispensing finished products. Some Class A pharmacies hold additional Class A-S (sterile compounding) endorsements that allow limited sterile preparations. Most Texas chain and independent pharmacies hold Class A permits.
- Class A-SC (sterile compounding): A specialized endorsement for Class A pharmacies that prepare sterile compounded medications. GLP-1 compounding requires sterile facilities, so 503A pharmacies serving Texas patients hold either Class A-SC or equivalent permits.
- Class E (nonresident pharmacy): Required for any out-of-state pharmacy shipping prescriptions to Texas residents. Class E permit applications are reviewed by TSBP and verification is straightforward through public records.
- Class C (institutional pharmacy): Hospital-based pharmacies; not typically relevant to outpatient GLP-1 prescribing.
- 503B outsourcing facilities: A separate federal category (not a Texas permit class) for facilities producing bulk compounded preparations. The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List in 2026; the public comment period closed June 29, 2026. The outcome of that rulemaking affects 503B operations but not 503A patient-specific compounding.
Telehealth prescribing rules in Texas
Texas allows GLP-1 prescribing via telehealth without an in-person visit when the practitioner-patient relationship is established through synchronous video evaluation. The relevant authorities are the Texas Medical Board (for physicians) and the Texas Board of Nursing (for advanced practice registered nurses).
Practitioner-patient relationship
Texas Medical Board rules require that a valid practitioner-patient relationship be established before prescribing. This can be done via synchronous telehealth (real-time audio and video) and does not require an in-person visit for non-controlled substances. The practitioner must take an appropriate history, identify the patient, document the visit, and arrange follow-up.
Texas licensure required
The prescribing practitioner must hold an active Texas medical license, Texas osteopathic license, or Texas APRN license with prescriptive authority. Reciprocity does not apply to prescribing; a practitioner licensed in another state cannot prescribe to a Texas resident based on that out-of-state license alone.
APRN prescribing in Texas
Texas requires APRNs to practice under a prescriptive authority agreement with a delegating physician. This is more restrictive than full-practice authority states like Florida. Most Texas-serving telehealth providers structure their practitioner panels accordingly, with physician oversight built into the prescribing workflow.
The post-shortage compounding landscape
The FDA declared the semaglutide shortage resolved on February 21, 2025, and the tirzepatide shortage resolved on December 19, 2024. The end of the shortage triggered changes in how compounding for these molecules is permitted under federal law.
The headline change is that 503B outsourcing facilities lost the shortage-period authorization to produce semaglutide and tirzepatide for office stock and similar uses. 503A patient-specific compounding (the form most telehealth prescribing relies on) remains legal under federal law when:
- The medication is prepared pursuant to a valid prescription for an individually identified patient.
- The compounded preparation is not "essentially a copy" of an FDA-approved commercial product.
- The compounding is performed by a licensed pharmacist or licensed physician in a state-licensed pharmacy.
The "essentially a copy" standard is the focus of ongoing FDA enforcement. The April 2026 FDA reiteration emphasized that compounded preparations marketed as alternative versions of branded products at lower prices, without documented patient-specific clinical justification, are not protected by the 503A exemption. Texas-serving telehealth programs that comply with this standard typically document one or more of: documented clinical justification (such as the need for a specific dose strength not commercially available, an adjuvant additive like cyanocobalamin, a different injection volume or vial format) or patient-specific medical necessity (such as an allergy or intolerance to an excipient in the commercial product).
Texas Board of Pharmacy enforcement
The TSBP has been more active than most state pharmacy boards in pursuing compounding violations. Notable actions in recent years:
- Salt-form tirzepatide prosecutions: TSBP has investigated and disciplined pharmacies dispensing tirzepatide as a salt form (rather than the FDA-approved base form). Salt-form preparations have been a focus of FDA enforcement nationally and are not considered equivalent to the commercial product. Patients should verify with their pharmacy that the active ingredient is the base form of semaglutide or tirzepatide, not a salt variant.
- Nonresident permit enforcement: Out-of-state pharmacies shipping to Texas without a Class E permit have been subject to cease-and-desist actions and discipline.
- Sterile compounding inspections: TSBP conducts inspections of Class A-SC pharmacies, with public inspection records available through the Board's website.
Coverage in Texas
Texas Medicaid: Does not cover GLP-1 medications for weight loss in adults. Coverage is available for Type 2 diabetes through the standard preferred drug list with prior authorization.
Commercial insurance: Major Texas insurers (Blue Cross Blue Shield of Texas, UnitedHealthcare, Aetna, Cigna, Humana) generally cover Wegovy or Zepbound for adults meeting BMI criteria with prior authorization and step therapy requirements. Self-insured employer plans set their own rules and vary widely. The largest Texas employers (energy, healthcare, technology) often include GLP-1 coverage in their plans; smaller employers often exclude them.
Medicare: Standard Medicare coverage rules apply. Wegovy is covered for the cardiovascular indication based on the FDA's 2024 approval. Weight loss alone is not covered under Medicare Part D.
Cash-pay price ranges in Texas
Pricing for cash-pay Texas patients tracks the national pattern with mild regional variation. Typical 2026 monthly costs:
- Telehealth compounded semaglutide: $179 to $349 per month depending on dose, provider, and plan length. Multi-month plans typically discount the per-month rate. Texas patients receive shipments from out-of-state Class E nonresident pharmacies in most telehealth programs.
- NovoCare direct Wegovy: $499 per month for all doses.
- LillyDirect Zepbound vials: $349 per month for 2.5 mg and 5 mg, $449 per month for higher doses.
- Retail uninsured branded: $1,059 to $1,349 per month.
- HSA and FSA reimbursement: Available with a Letter of Medical Necessity for both branded and compounded products. Effective discount typically 22 to 32 percent based on marginal tax rate.
What Texas patients should verify before paying
Practitioner Texas licensure
The prescribing clinician must hold an active Texas medical license, osteopathic license, or APRN license with prescriptive authority. Verification is available through the Texas Medical Board public licensee lookup and the Texas Board of Nursing public lookup.
Pharmacy Texas permit
If the dispensing pharmacy is in Texas, it should hold a Class A or Class A-S permit. If the dispensing pharmacy is out of state and shipping to a Texas address, it must hold a Class E nonresident permit. TSBP publishes a public licensee lookup; pharmacy name, license number, and permit class are public records.
Active pharmaceutical ingredient form
The compounded preparation should use the base form of semaglutide or tirzepatide, not a salt form. Salt-form preparations have been the focus of TSBP enforcement and are not considered equivalent to the FDA-approved commercial product. Reputable pharmacies will provide documentation of the API source and form.
Synchronous evaluation
The intake must include a real-time audio and video evaluation with the prescribing practitioner, not just an asynchronous form. This is required by Texas Medical Board rules and is a marker of programs operating within the legal framework.
Follow-up included
Programs should include follow-up visits for dose adjustments and side effect management. Standard intervals are every 30 to 90 days during titration. Texas's APRN prescriptive authority structure usually has physician involvement built into the workflow.
Geographic considerations within Texas
The major Texas metros (Houston, Dallas-Fort Worth, San Antonio, Austin) have the highest density of in-person GLP-1 providers and sterile compounding pharmacies. The Rio Grande Valley, the Panhandle, and the rural eastern counties have fewer in-person options. Telehealth coverage is statewide. Shipping logistics are generally reliable across the state with the exception of weather events; severe winter weather (notable example February 2021) can delay shipments by several days.
Frequently asked questions
Is compounded semaglutide legal in Texas in 2026? Yes, when prepared by a state-licensed 503A pharmacy for an individual patient with a valid prescription from a Texas-licensed practitioner and with documented clinical justification consistent with federal 503A rules. The FDA has issued guidance and proposed additional restrictions, but 503A patient-specific compounding remains a legal pathway.
Can a Texas resident use a telehealth program based in another state? The company can be headquartered anywhere, but the prescribing practitioner must be Texas-licensed and the dispensing pharmacy must have a Texas nonresident pharmacy permit (Class E). Reputable cross-state programs comply with both requirements.
Why has the Texas Board of Pharmacy been more visible than other state boards on compounded GLP-1s? TSBP has a long-standing reputation for active enforcement, and the volume of Texas patients combined with the visibility of GLP-1 prescribing has put compounding practices under more scrutiny than in smaller markets. The Board's actions have generally targeted clear violations (salt-form preparations, unpermitted dispensing) rather than legitimate 503A practice.
What happens if my pharmacy is found to be operating without proper Texas permits? Patients are not penalized for receiving prescriptions from non-compliant pharmacies. The risk is product quality, since unpermitted pharmacies are not subject to TSBP inspection. Patients in this situation should request prescription transfer to a Texas-licensed or properly Class E-permitted pharmacy.
Does Texas Medicaid cover GLP-1s under any circumstances for weight loss? Not as of 2026. Texas Medicaid covers GLP-1s for Type 2 diabetes through the standard prior authorization process. There is no current policy proposal to add weight loss as a covered indication.
The Bottom Line
Texas is a fully accessible state for GLP-1 prescribing via telehealth, with a regulatory framework that requires more attention to detail than some others. The realistic cash-pay range tracks the national pattern from $179 per month (compounded multi-month) to $499 per month (NovoCare direct Wegovy). Patients should verify Texas licensure of the prescriber, Class A or Class E permit status of the pharmacy, base-form API for compounded preparations, and synchronous video evaluation as part of the intake. The Texas State Board of Pharmacy's active enforcement is a feature, not a bug; it favors patients working with programs that maintain compliant operations.
CLYR Health serves Texas residents with Texas-licensed practitioners, properly permitted 503A pharmacy fulfillment, and flat-rate pricing across all doses. Start your assessment at /intake.html.